A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Chu, Fong Fong, Ph.D. Laboratory Bookmark and Share

Laboratory of Fong Fong Chu, Ph.D.

Glutathione Peroxidase in Mouse Inflammatory Bowel Disease and Radiation Protection
Inflammatory bowel disease (IBD) is consisted of Crohn’s disease, which always involves the ileum, and ulcerative colitis, which always involves the colon.  About one to two per thousand Americans are diagnosed with IBD each year, and most people diagnosed of Crohn’s disease are between 15-30 years old, when most people diagnosed of ulcerative colitis are in their 30s (www.ccfa.org).  Although IBD is not a life-threatening disease, it is painful, needs long-term management, and increases cancer risk in the ileum, the colon, and the rectum.
 
To better manage this disease, we need to better understand the cause and the progression of this disease. Many animal IBD models have been generated and analyzed for IBD etiology and treatment. Most studied animal IBD models are mouse models for ulcerative colitis.  There are only a couple of mouse models for Crohn’s disease, SAMP1/Yit mice and TNFΔARE mice, which overexpress tumor necrosis factor. We have recently generated a new mouse model for Crohn’s disease, by disruption of genes encoding for two Se-dependent glutathione peroxidases (GPXs), Gpx1 and Gpx2.  Gpx1/2-double knockout (DKO) mice have more severe ilealitis than colitis, and ten-times more of ileal tumors than colonic tumors.
 
There are three major factors in IBD etiology: genetic, environmental, and immunological; all have been confirmed in Gpx1/2-DKO mice.  Among the mouse inbred lines that we have studied, Gpx1/2-DKO mice on a pure 129/SvJ (129) genetic background have the worst pathology and symptoms; DKO mice on a mixed C57BL/6J (B6) and 129 (B6.129) genetic background still have intermediate symptom and pathology; when B6 DKO mice have very mild disease.  This disease is induced by luminal microflora, since germ-free Gpx1/2-DKO mice are disease-free.  Although these DKO mice are highly sensitive to certain microflora, the identity of the pathogens remains to be elusive.
 
Another important environmental factor affecting IBD outcome is the diet.  We have found DKO mice on defined diets have much better health than those on commercial rodent chows. Since dietary modulation provides the best health for these DKO mice than many conventional and experimental drugs for IBD, we plan to identify the component of diet that cause ileocolitis.
 
Increased in reactive oxygen species (ROS) has been observed in inflamed intestinal mucosa in IBD patients, however, it is believed to be caused by inflammation. ROS is also known to activate many pro-inflammatory cytokines presumably by activation of nuclear factor (NF) κB pathway, thus the ROS generated from inflammatory cells adds fuel to the fire and further damage the tissue. We are investigating that whether GPX protects intestinal epithelial cells from oxidative stress, and what are the downstream genes affected by GPX activity.
 
In addition to the role of GPX in prevention of ileocolitis that we have recently discovered, the antioxidant activity of GPX has long been suspected to protect cells against radiation damage. However, there is little evidence to support this claim.  Additionally, whether the radioprotective effect of Amifostine, a small molecule with superoxide dismutase activity, depends on GPX to reduce hydrogen peroxide is not known.  We plan to evaluate the role of GPX in protection of intestinal epithelial cells against γ-irradiation in near future.
 

Fong Fong Chu, Ph.D. Lab Members

Avo Artinyan, M.D.
Surgical Oncology Fellow
Ph 626-256-HOPE (4673)
Ext. 67100
Fax 626-930-5330
AArtinyan@coh.org
 
Steve Esworthy, Ph.D.
Assistant Research Scientist
Ph 626-256-HOPE (4673)
Ext. 62819
Fax 626-930-5330
SEsworthy@coh.org
 
Qiang Gao, M.D., Ph.D.
Research Fellow
Ph 626-256-HOPE (4673)
Ext. 65589
Fax 626-930-5330
QGao@coh.org
 
Byung-Wook Kim, M.S.
Research Associate I
Ph 626-256-HOPE (4673)
Ext. 62955
Fax 626-930-5330
bkim@coh.org
 
Marucha Sanchez
Research Associate I
Ph 626-256-HOPE (4673)
Ext. 60412
Fax 626-930-5330
msanchez2@coh.org
 

Chu, Fong Fong, Ph.D. Laboratory

Laboratory of Fong Fong Chu, Ph.D.

Glutathione Peroxidase in Mouse Inflammatory Bowel Disease and Radiation Protection
Inflammatory bowel disease (IBD) is consisted of Crohn’s disease, which always involves the ileum, and ulcerative colitis, which always involves the colon.  About one to two per thousand Americans are diagnosed with IBD each year, and most people diagnosed of Crohn’s disease are between 15-30 years old, when most people diagnosed of ulcerative colitis are in their 30s (www.ccfa.org).  Although IBD is not a life-threatening disease, it is painful, needs long-term management, and increases cancer risk in the ileum, the colon, and the rectum.
 
To better manage this disease, we need to better understand the cause and the progression of this disease. Many animal IBD models have been generated and analyzed for IBD etiology and treatment. Most studied animal IBD models are mouse models for ulcerative colitis.  There are only a couple of mouse models for Crohn’s disease, SAMP1/Yit mice and TNFΔARE mice, which overexpress tumor necrosis factor. We have recently generated a new mouse model for Crohn’s disease, by disruption of genes encoding for two Se-dependent glutathione peroxidases (GPXs), Gpx1 and Gpx2.  Gpx1/2-double knockout (DKO) mice have more severe ilealitis than colitis, and ten-times more of ileal tumors than colonic tumors.
 
There are three major factors in IBD etiology: genetic, environmental, and immunological; all have been confirmed in Gpx1/2-DKO mice.  Among the mouse inbred lines that we have studied, Gpx1/2-DKO mice on a pure 129/SvJ (129) genetic background have the worst pathology and symptoms; DKO mice on a mixed C57BL/6J (B6) and 129 (B6.129) genetic background still have intermediate symptom and pathology; when B6 DKO mice have very mild disease.  This disease is induced by luminal microflora, since germ-free Gpx1/2-DKO mice are disease-free.  Although these DKO mice are highly sensitive to certain microflora, the identity of the pathogens remains to be elusive.
 
Another important environmental factor affecting IBD outcome is the diet.  We have found DKO mice on defined diets have much better health than those on commercial rodent chows. Since dietary modulation provides the best health for these DKO mice than many conventional and experimental drugs for IBD, we plan to identify the component of diet that cause ileocolitis.
 
Increased in reactive oxygen species (ROS) has been observed in inflamed intestinal mucosa in IBD patients, however, it is believed to be caused by inflammation. ROS is also known to activate many pro-inflammatory cytokines presumably by activation of nuclear factor (NF) κB pathway, thus the ROS generated from inflammatory cells adds fuel to the fire and further damage the tissue. We are investigating that whether GPX protects intestinal epithelial cells from oxidative stress, and what are the downstream genes affected by GPX activity.
 
In addition to the role of GPX in prevention of ileocolitis that we have recently discovered, the antioxidant activity of GPX has long been suspected to protect cells against radiation damage. However, there is little evidence to support this claim.  Additionally, whether the radioprotective effect of Amifostine, a small molecule with superoxide dismutase activity, depends on GPX to reduce hydrogen peroxide is not known.  We plan to evaluate the role of GPX in protection of intestinal epithelial cells against γ-irradiation in near future.
 

Lab Members

Fong Fong Chu, Ph.D. Lab Members

Avo Artinyan, M.D.
Surgical Oncology Fellow
Ph 626-256-HOPE (4673)
Ext. 67100
Fax 626-930-5330
AArtinyan@coh.org
 
Steve Esworthy, Ph.D.
Assistant Research Scientist
Ph 626-256-HOPE (4673)
Ext. 62819
Fax 626-930-5330
SEsworthy@coh.org
 
Qiang Gao, M.D., Ph.D.
Research Fellow
Ph 626-256-HOPE (4673)
Ext. 65589
Fax 626-930-5330
QGao@coh.org
 
Byung-Wook Kim, M.S.
Research Associate I
Ph 626-256-HOPE (4673)
Ext. 62955
Fax 626-930-5330
bkim@coh.org
 
Marucha Sanchez
Research Associate I
Ph 626-256-HOPE (4673)
Ext. 60412
Fax 626-930-5330
msanchez2@coh.org
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • Beyond the pink ribbons, special product fundraisers, and the pastel sea of color that marks October, Breast Cancer Awareness Month offers a reason to celebrate and to reflect. More than 2.8 million breast cancer survivors live in the U.S. They are survivors of the second most-common cancer in women, behind ski...
  • Gliomas, a type of tumor that grows in the brain, are very difficult to treat successfully due to their complex nature. That might not always be the case. First some background: The most aggressive and common type of primary brain tumor in adults is glioblastoma. Although the brain tumor mass can often be remov...
  • Cutaneous T cell lymphomas are types of non-Hodgkin lymphoma that arise when infection-fighting white blood cells in the lymphatic system – called lymphocytes – become malignant and affect the skin. The result is rashes and, sometimes, tumors, which can be mistaken for other dermatological conditions. In a smal...
  • Weighing your breast cancer risk? One study suggests a measure to consider is skirt size. A British study suggests that for each increase in skirt size every 10 years after age 25, the five-year risk of developing breast cancer postmenopause increases from one in 61 to one in 51 – a 77 percent increase in risk....
  • Runners prize medals for 5Ks and marathons. Becky Stokes has a medal she cherishes from a very different kind of race: the marathon of treatments necessary to beat her aggressive triple-negative breast cancer. Just a week ago, she completed her last radiation treatment, and danced in the hospital with the staff...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. Darakjian’s s...
  • The environment plays a role in causing cancer – this much we know. But scientists are still trying to understand what that role is, what environmental factors are in play and how precisely those factors are linked to cancer. Now City of Hope researchers have unlocked a clue as to how one carcinogen triggers ca...
  • Jonathan Yamzon, M.D., assistant clinical professor of surgery in the Division of Urology and Urologic Oncology, explains his approach to what’s known as “active surveillance” of men with prostate cancer. Patients need to be educated about their treatment options, he writes. Active surveillanc...
  • For most prostate cancer patients, surgery or radiation therapy is the initial and primary treatment against the disease. But some patients can benefit from chemotherapy and hormone therapy too, especially if there are signs of a relapse or if the cancer has spread beyond the prostate gland. Here, Cy Stein, M.D...
  • Cancer research has yielded scientific breakthroughs that offer patients more options, more hope for survival and a higher quality of life than ever before. The 14.5 million cancer patients living in the United States are living proof that cancer research saves lives. Now, in addition to the clinic, hospital an...
  • Advances in cancer treatment, built on discoveries made in the laboratory then brought to the bedside, have phenomenally changed the reality of living with a cancer diagnosis. More than any other time in history, people diagnosed with cancer are more likely to survive and to enjoy a high quality of life. Howeve...
  • While health care reform has led to an increase in the number of people signing up for health insurance, many people remain uninsured or are not taking full advantage of the health benefits they now have. Still others are finding that, although their premiums are affordable, they aren’t able to see the do...
  • Kidney cancer rates and thyroid cancer rates in adults have continued to rise year after year. Now a new study has found that incidence rates for these cancers are also increasing in children — particularly in African-American children. The study, published online this month in Pediatrics, examined childhood ca...
  • Thyroid cancer has become one of the fastest-growing cancers in the United States for both men and women. The chance of being diagnosed with the cancer has nearly doubled since 1990. This year an estimated 63,000 people will be diagnosed with thyroid cancer in the United States and nearly 1,900 people will die ...
  • Older teenagers and young adults traditionally face worse outcomes than younger children when diagnosed with brain cancer and other central nervous system tumors. A first-of-its-kind study shows why. A team of researchers from the departments of Population Sciences and Pathology at City of Hope recently examine...